Redeye considers the results of Asarina Pharma’s phase IIb trial, to be presented at the end of April, as one of the highlights on the Scandinavian biotech scene this year. We set the likelihood for a positive outcome to 50 percent in the phase IIb trial and see an attractive risk/reward at current share levels.